Novus Biologicals

Novus Biologicals is a biotechnology company based in Centennial, Colorado that develops, licenses, and markets research materials for the scientific market. The company focuses on providing research-grade antibodies for academic, corporate, and government laboratories. Novus Biologicals was acquired by Bio-Techne in 2014 and is now part of their portfolio of biotechnology and innovation companies.

Novus Biologicals
TypePublic company
IndustryBiotech, Life sciences
Founded1996
Headquarters
Centennial, Colorado
,
USA
ProductsAntibodies, proteins and peptides, lysates, activators and inhibitors, ELISA kits, antibody conjugation kits, as well as custom products.
Websitewww.novusbio.com

History

Novus Biologicals was founded in 1996 by Karen Padgett to innovate and provide advanced solutions for all applications and areas of scientific research. Novus products are utilized in many different research areas, including autophagy, hypoxia, immunology, cancer, signal transduction, cell biology, stem cell markers, DNA repair, metabolism, cell cycle and replication, GPCR, protein kinases and apoptosis.

In 2008, Novus became a limited liability company when Mainsail Partners invested in the company. After years of significant growth in the biotechnology industry, Novus increased their brand awareness and customer base significantly. Novus Biologicals was selected by Inc. Magazine as one of the fastest-growing private companies in America 8 out of the last 12 years.[1] In 2010, Novus Biologicals was announced as one of the top 50 private companies to watch in Colorado by ColoradoBIZ.[2]

In 2013, Novus Biologicals acquired Imgenex – a first big step in building their catalog of products.[3] In 2014, antibody and reagent supplier Bio-Techne acquired Novus Biologicals for $60 million.[4] The acquisition was meant to provide scientists and doctors a broader selection of products in one location.[5] Bio-Techne has more than 30 sites worldwide and sells their products directly to customers in the biotechnology research field.[6] As of 2019, Bio-Techne has acquired over 15 companies and has over 2,200 employees across the globe.[7]

References
  1. "Novus Biologicals". Inc.com. Retrieved 2019-07-23.
  2. "50 Colorado companies: Fueling the economic fire". www.cobizmag.com. Retrieved 2019-07-23.
  3. "Novus Buys Imgenex, "First Step" in Growing Catalog by Acquisition". GEN - Genetic Engineering and Biotechnology News. 2013-10-31. Retrieved 2019-07-23.
  4. Bio-Techne. "Bio-Techne Announces Agreement To Acquire Novus Biologicals". www.prnewswire.com (Press release). Retrieved 2019-07-23.
  5. "Bio-Techne Acquires Novus Biologicals for $60M". GEN - Genetic Engineering and Biotechnology News. 2014-07-03. Retrieved 2019-10-28.
  6. "Bio-Techne Corp (TECH) SEC Filings". NASDAQ.com. Retrieved 2019-07-23.
  7. "Life Science & Diagnostic Brands: Bio-Techne". www.bio-techne.com. Retrieved 2019-07-23.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.